[XLS] revenue reclassification a-2 - Investor Relations | Adaptive ...,https://investors.adaptivebiotech.com/static-files/a71f7f43-57a6-4a83-b6cf-75ae748b9093
[XLS] gracell biotechnologies inc A B C D E F G 1 2 Gracell ...,https://ir.gracellbio.com/static-files/6bf97483-347b-46ad-a3aa-2c51b1e0df20
[XLS] name_and_title - cloudfront.net,https://d18rn0p25nwr6d.cloudfront.net/CIK-0001501756/0084f58c-6207-4a48-b033-456b13da7392.xls
[XLS] Table_Of_Contents - cloudfront.net,https://d18rn0p25nwr6d.cloudfront.net/CIK-0001501756/e4bcad0a-d313-422a-b900-d24951f354ae.xls
[XLS] lion biotechnologies inc A B C D E F 1 2 Lion Biotechnologies INC 3 ...,https://ir.iovance.com/static-files/70cffd88-2f2f-455f-b29a-e10663f12abf
[XLS] Table A B 1 2 Nevada 75-3254381 3 (State or other jurisdiction of ...,https://ir.iovance.com/static-files/18708df5-9497-425e-8e04-4459a616dd04
[XLS] pursuant to 17 cfr section-1 - Maravai LifeSciences,https://investors.maravai.com/static-files/e2c76a66-8d7f-47da-bb9f-040214de57ae
[XLS] Table-1 - Altimmune,https://ir.altimmune.com/static-files/419433bb-0ec8-4404-8558-3165d16646b0
[XLS] biotech_nano_f A B C D E F G H I J K L M N O P Q R S T U 1 ...,https://www.oecd-ilibrary.org/depenses-de-r-d-en-biotechnologies-et-en-nanotechnologies-dans-le-secteur-des-entreprises-2013_5jm3pmqq64nq.xls%3FitemId%3D%252Fcontent%252Fcomponent%252F9789264246669-graph217-fr%26mimeType%3Dvnd.ms-excel
